Associated Papers
Novel somatic alterations underlie Chinese papillary thyroid carcinoma.
Yang C et al.
Cancer Biomarkers : Section a of Disease Markers, 2020
32065787 (PubMed )
Supplement: sj-xlsx-1-cbm-10.3233_cbm-191200.xlsx › Table_S5
Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma.
Cornelius A et al.
Frontiers in Pharmacology, 2017
28993730 (PubMed )
Supplement: Table3.xlsx › Germline
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › M121224
iFish: predicting the pathogenicity of human nonsynonymous variants using gene-specific/family-specific attributes and classifiers.
Wang M et al.
Scientific Reports, 2016
27527004 (PubMed )
Supplement: srep31321-s5.xls › VaribenchSelectedPure
Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Kim SY et al.
Oncotarget, 2015
25831047 (PubMed )
Supplement: oncotarget-06-7597-s002.xlsx › Table_S1
Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
Choi J et al.
Pigment Cell & Melanoma Research, 2014
24283590 (PubMed )
Supplement: pcmr0027-0253-SD5.pdf
Select a paper to view details